Magnitude Biosciences: Funding, Investors & Team (Sep 2026)
An innovative C elegans company that serves the biotech, nutrition, and other industries and fields of study by combining our knowledge and technology to produce quantitative non-invasive assays of health outcomes. - Find efficient and safe dosage ranges by prescreening compounds to minimize the number of trials on mammals Testing mutants in signaling pathways, screening mutant libraries, screening compound libraries, combining compounds and mutants, and adapting technology to your needs. We are a group of professionals with a track record that includes: customizing C elegans studies to address your particular ageing research questions incorporating C. elegans into pipelines for drug discovery working with cutting-edge biotech and pharmaceutical businesses delivering pertinent, consistent, and data-rich assays
Magnitude Biosciences has raised $1.8M across 2 funding rounds on record, the most recent an undisclosed round of $1.8M announced in Sep 2026.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Magnitude Biosciences Company Profile and Key Stats
Latest funding round on record: Sep 2026.
Magnitude Biosciences Funding Rounds
1 of 2 rounds was announced without a disclosed amount and is excluded from the total.
Magnitude Biosciences announced a Seed in Nov 2022; the amount was not disclosed.
3.8 years later, an undisclosed round of $1.8M was announced in Sep 2026.
Magnitude Biosciences Investors
7 investors are recorded in total; the 5 named above are those the record identifies.
Magnitude Biosciences Founders and Leadership Team
Contact details for the Magnitude Biosciences team: 2 of 2 have an email address on file, 1 has a LinkedIn profile.
Start 14-day free trial →Magnitude Biosciences Funding Compared to Other Biotechnology Startups
Magnitude Biosciences' latest round of $1.8M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Magnitude Biosciences in Biotechnology and Durham
Companies Similar to Magnitude Biosciences
ViaNautis, previously known as SomaServe, was established in 2018 as a separate entity from UCL under the…
Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of…
Biodexa Pharmaceuticals is an international specialty pharmaceutical company focused on oncology and other…
Concert Bio helps businesses create optimal microbial communities.
RQ Bio is a biotechnology company that develops long-acting monoclonal antibodies against seasonal influenza…
N4 Pharma is a drug reformulation company focused on developing and out licensing new versions of existing…
Laverock Therapeutics is working on developing a system for suppressing genes, which can be used to create…
Oak hill bio is a clinical-stage rare disease therapeutics company developing life-changing medicines.
IMU is a discovery engine mapping the immune system to advance precision medicine.
Mykor is a climate tech start-up. It decarbonizes the construction industry by manufacturing carbon-negative…
Neurovalens provides cutting-edge solutions in the realms of neuroscience, bioscience, and neurophysiology.…
Voxmind's biometric confirmation and authentication platform that provides voice based biometrics that helps…
Magnitude Biosciences Funding FAQs
What does Magnitude Biosciences do?
An innovative C elegans company that serves the biotech, nutrition, and other industries and fields of study by combining our knowledge and technology to produce quantitative non-invasive assays of health outcomes. - Find efficient and safe dosage ranges by prescreening compounds to minimize the number of trials on mammals Testing mutants in signaling pathways, screening mutant libraries, screening compound libraries, combining compounds and mutants, and adapting technology to your needs. We are a group of professionals with a track record that includes: customizing C elegans studies to address your particular ageing research questions incorporating C. elegans into pipelines for drug discovery working with cutting-edge biotech and pharmaceutical businesses delivering pertinent, consistent, and data-rich assays
How much funding has Magnitude Biosciences raised?
Magnitude Biosciences has raised $1.8M across 2 rounds on record. The most recent is an undisclosed round of $1.8M announced in Sep 2026.
When did Magnitude Biosciences last raise funding?
Magnitude Biosciences' most recent funding round on record is an undisclosed round of $1.8M, announced in Sep 2026.
Who has invested in Magnitude Biosciences?
Investors on record for Magnitude Biosciences include Northstar Ventures, Innovate UK, Finance Durham Fund, Future Fund, North East Fund. FundedIQ records 7 investors in total.
Who is the CEO of Magnitude Biosciences?
Fozia Saleem is listed as Chief Executive Officer at Magnitude Biosciences.
Where is Magnitude Biosciences headquartered?
Magnitude Biosciences is based in Durham, United Kingdom.
How many employees does Magnitude Biosciences have?
Magnitude Biosciences is in the 11-50 employee band.
When was Magnitude Biosciences founded?
Magnitude Biosciences was founded in 2018.
How does Magnitude Biosciences' funding compare to other Biotechnology startups?
Magnitude Biosciences' latest round of $1.8M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,183 tracked companies over the last two years.
About FundedIQ's Magnitude Biosciences Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Magnitude Biosciences is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.